Chronic Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant [Phase 2, Phase 3]
A Phase 2/3 clinical trial comparing thymoglobulin to alemtuzumab in patients undergoing allogeneic stem cell transplantation has been compl…
-
CLINICAL_TRIALS trial_result · 2023-03-01Clinical Trial Update: The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) [Phase 2]
Phase 2 clinical trial update for the LAST study evaluating outcomes after stopping tyrosine kinase inhibitors in chronic myeloid leukemia.
-
FDA approval · 2023-02-08FDA Approved: DASATINIB — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for Dasatinib submitted by Prasco Laboratories. The action approves an additional submission under N…
-
CLINICAL_TRIALS trial_result · 2023-02-03Clinical Trial Update: Bosutinib in Elderly Chronic Myeloid Leukemia [Phase 2]
Phase 2 trial update for bosutinib in elderly patients with chronic myeloid leukemia has completed.
-
FDA approval · 2023-01-31FDA Approved: IMATINIB MESYLATE — Supplemental Application (BluePoint Laboratories)
FDA approves a supplemental application for Imatinib Mesylate from BluePoint Laboratories under an ANDA, confirming approval of a generic pr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-01-31Clinical Trial Update: Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention [Phase 3]
Phase 3 trial comparing Tacrolimus plus mini-methotrexate versus Tacrolimus plus methotrexate for graft-versus-host disease prevention has c…
-
CLINICAL_TRIALS trial_result · 2023-01-25Clinical Trial Update: Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia [Phase 2]
Phase 2 trial comparing imatinib or nilotinib with pegylated interferon-α2b in chronic myeloid leukemia; study terminated with results poste…
-
CLINICAL_TRIALS trial_result · 2022-12-16Clinical Trial Update: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation [Phase 3]
A Phase 3 randomized trial comparing Fludarabine and Busulfan versus Fludarabine, Busulfan plus Total Body Irradiation in patients with myel…
-
CLINICAL_TRIALS trial_result · 2022-12-08Clinical Trial Update: Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. [Phase 2]
Phase 2 trial update on conditioning regimens for transplantation of unrelated donor umbilical cord blood in patients with hematologic malig…
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies [Phase 2]
Phase 2 clinical trial update on shorter course tacrolimus after non-myeloablative conditioning with related donor PBSCT and high-dose postt…
-
CLINICAL_TRIALS trial_result · 2022-10-25Clinical Trial Update: Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS [Phase 3]
Phase 3 trial comparing NiCord (omidubicel) stem cell transplantation to standard umbilical cord blood in patients with hematologic malignan…
-
CLINICAL_TRIALS trial_result · 2022-10-07Clinical Trial Update: Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow [Phase 2]
Phase 2 trial update on specialized blood cell transplants for cancers of the blood and bone marrow; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-08-18Clinical Trial Update: Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2) [Phase 2]
A multicenter single-arm Phase 2 pilot study evaluating the efficacy of nilotinib in chronic myeloid leukemia patients with molecular relaps…
-
CLINICAL_TRIALS trial_result · 2022-07-27Clinical Trial Update: Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP [Phase 4]
A Phase 4 trial update investigates using reduced-dose dasatinib (70 mg daily) as first-line treatment for newly diagnosed chronic myeloid l…
-
CLINICAL_TRIALS trial_result · 2022-07-22Clinical Trial Update: Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. [Phase 4]
Phase 4 clinical trial evaluating deep molecular response in adults with chronic-phase Chronic Myeloid Leukemia treated with nilotinib first…
-
EMA withdrawal · 2022-07-05EMA Withdrawn: Imatinib Actavis (imatinib) — Actavis Group PTC ehf
EMA withdrawn Imatinib Actavis (imatinib) from the market, with indications including chronic myeloid leukemia, precursor B-ALL/lymphoma, my…
-
FDA approval · 2022-06-21FDA Approved: IMATINIB MESYLATE — Original Application (Upsher-Smith Laboratories, LLC)
FDA approved an original application for imatinib mesylate (Upsher-Smith Laboratories) as a generic product. The approval supports its use f…
-
CLINICAL_TRIALS trial_result · 2022-06-13Clinical Trial Update: A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) [Phase 1, Phase 2]
Phase 1/2 trial update of ponatinib in Japanese patients with Chronic Myeloid Leukemia and Philadelphia chromosome-positive Acute Lymphoblas…
-
CLINICAL_TRIALS trial_result · 2022-04-07Clinical Trial Update: Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies [Phase 3]
Phase 3 clinical trial update on stem cell transplantation from partially HLA-m matched related donors for hematologic malignancies; trial c…
-
CLINICAL_TRIALS trial_result · 2022-03-25Clinical Trial Update: Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy [Phase 2]
Phase 2 trial investigating stem cell monitoring in chronic myeloid leukemia patients treated with nilotinib has completed with posted resul…
-
FDA approval · 2022-02-18FDA Approved: TASIGNA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Tasigna (nilotinib) submitted by Novartis Pharmaceuticals Corporation. The approval updates aspe…
-
CLINICAL_TRIALS trial_result · 2022-02-15Clinical Trial Update: Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs [Phase 3]
A Phase 3 trial comparing ABL001 (asciminib) to bosutinib in chronic myeloid leukemia in chronic phase patients previously treated with ≥2 T…
-
FDA approval · 2022-01-21FDA Approved: BUSULFAN — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Busulfan by Amneal Pharmaceuticals LLC, updating the approval for this generic product.
-
CLINICAL_TRIALS trial_result · 2022-01-20Clinical Trial Update: Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia [Phase 4]
A Phase 4 clinical trial update reports sustained treatment-free remission in patients with BCR-ABL+ chronic myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2022-01-18Clinical Trial Update: Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase [Phase 2]
Phase 2 trial investigating nilotinib as first-line therapy for chronic myeloid leukemia in early chronic phase has been completed.